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Risks of recurrent stroke and all serious vascular events after 
spontaneous intracerebral haemorrhage: pooled analyses of 
two population-based studies
Linxin Li*, Michael T C Poon*, Neshika E Samarasekera, Luke A Perry, Tom J Moullaali, Mark A Rodrigues, James J M Loan, 
Jacqueline Stephen, Christine Lerpiniere, Maria A Tuna, Sergei A Gutnikov, Wilhelm Kuker, Louise E Silver, Rustam Al-Shahi Salman†, 
Peter M Rothwell†
Summary 
Background Patients with stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) are at risk of 
recurrent ICH, ischaemic stroke, and other serious vascular events. We aimed to analyse these risks in population-based 
studies and compare them with the risks in RESTART, which assessed antiplatelet therapy after ICH. 
Methods We pooled individual patient data from two prospective, population-based inception cohort studies of all 
patients with an incident firs-in-a-lifetime ICH in Oxfordshire, England (Oxford Vascular Study; April 1, 2002, 
to Sept 28, 2018) and Lothian, Scotland, UK (Lothian Audit of the Treatment of Cerebral Haemorrhage; June 1, 2010, to 
May 31, 2013). We quantified the absolute and relative risks of recurrent ICH, ischaemic stroke, or any serious vascular 
event (non-fatal stroke, non-fatal myocardial infarction, or vascular death), stratified by ICH location (lobar vs non-
lobar) and comorbid atrial fibrillation (AF). We compared pooled event rates with those after allocation to avoid 
antiplatelet therapy in RESTART.
Findings Among 674 patients (mean age 74·7 years [SD 12·6], 320 [47%] men) with 1553 person-years of follow-up, 
46 recurrent ICHs (event rate 3·2 per 100 patient-years, 95% CI 2·0–5·1) and 25 ischaemic strokes (1·7 per 
100 patient-years, 0·8–3·3) were reported. Patients with lobar ICH (n=317) had higher risk of recurrent ICH (5·1 per 
100 patient-years, 95% CI 3·6–7·2) than patients with non-lobar ICH (n=355; 1·8 per 100 patient-years, 1·0–3·3; 
hazard ratio [HR] 3·2, 95% CI 1·6–6·3; p=0·0010), but there was no evidence of a difference in the risk of ischaemic 
stroke (1·8 per 100 patient-years, 1·0–3·2, vs 1·6 per 100 patient-years, 0·6–4·4; HR 1·1, 95% CI 0·5–2·8). Conversely, 
there was no evidence of a difference in recurrent ICH rate in patients with AF (n=147; 3·3 per 100 patient-years, 
95% CI 1·0–10·7) compared with those without (n=526; 3·2 per 100 patient-years, 2·2–4·7; HR 0·9, 95% CI 0·4–2·1), 
but the risk of ischaemic stroke was higher with AF (6·3 per 100 patient-years, 3·7–10·9, vs 0·7 per 100 patient-years, 
0·1–5·6; HR 8·2, 3·3–20·3; p<0·0001), resulting in patients with AF having a higher risk of all serious vascular events 
than patients without AF (15·5 per 100 patient-years, 10·0–24·1, vs 6·8 per 100 patient-years, 3·6–12·5; HR 1·78, 
95% CI 1·16–2·74; p=0·0090). Only for patients with lobar ICH without comorbid AF was the risk of recurrent ICH 
greater than the risk of ischaemic stroke (5·2 per 100 patient-years, 95% CI 3·6–7·5, vs 0·9 per 100 patient-years, 
0·2–4·8; p=0·00034). Comparing data from the pooled population-based studies with that from patients allocated to 
not receive antiplatelet therapy in RESTART, there was no evidence of a difference in the rate of recurrent ICH (3·5 per 
100 patient-years, 95% CI 1·9–6·0, vs 4·4 per 100 patient-years, 2·6–6·1) or ischaemic stroke (3·4 per 100 patient-years, 
1·9–5·9, vs 5·3 per 100 patient-years, 3·3–7·2).
Interpretation The risks of recurrent ICH, ischaemic stroke, and all serious vascular events after ICH differ by ICH 
location and comorbid AF. These data enable risk stratification of patients in clinical practice and ongoing 
randomised trials.
Funding UK Medical Research Council, Stroke Association, British Heart Foundation, Wellcome Trust, and the 
National Institute for Health Research Oxford Biomedical Research Centre.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Worldwide, stroke due to spontaneous (non-traumatic) 
intracerebral haemorrhage (ICH) accounts for approxi-
mately a quarter of all strokes but almost half of the 
disability-adjusted life-years lost owing to stroke,1,2 because 
of the subsequent risks of death, disability, and serious 
vascular events. Adults with ICH usually have underlying 
cerebral small vessel disease,3 which leaves them at risk 
of recurrent stroke4 and systemic comorbidities, which 
put them at additional risk of stroke and other cardio-
vascular events.5,6
Overall, according to data from seven cohorts,6–9 ICH 
survivors seem to have a similar annual risk of recurrent 
ICH (1·1–3·9%) and ischaemic stroke (1·1–3·2%). 
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However, these estimates of the risk of stroke recurrence 
originate mostly from hospital-based studies. Although a 
recent study8 reported major ischaemic and haemorrhagic 
events after ICH in a cohort of 560 patients, little is known 
about the risks of all serious vascular events.
Identifying risk factors for recurrent ICH, ischaemic 
stroke, and all serious vascular events after ICH could 
help with risk stratification to inform decisions about 
antithrombotic drugs after ICH. Lobar ICH location has 
been associated with a higher risk of recurrent ICH in 
some studies,5,6,8–12 but not others.13,14 The risk of recurrent 
stroke is particularly high in the first few days and weeks 
after transient ischaemic attack (TIA) or ischaemic 
stroke,15 although less is known about the time course of 
recurrent ICH. Some studies have found that the risks of 
recurrent ICH were particularly high in the first year 
after ICH,16,17 although most studies only included 30-day 
survivors so they are likely to have underestimated the 
true early risk. Risk factors for ischaemic stroke after 
ICH are also unclear. Although ICH location does not 
seem to be associated with the risk of ischaemic stroke,6,8,9 
atrial fibrillation (AF) is likely to be a risk factor for 
ischaemic stroke, but not recurrent ICH.18
In 2019, findings from RESTART19 showed that after 
ICH associated with antithrombotic drug use, survivors 
had a numerically but non-significantly lower risk 
of recurrent ICH after starting antiplatelet therapy com-
pared with avoiding these drugs (adjusted hazard ratio 
[HR] 0·51, 95% CI 0·25–1·03; p=0·060). However, 
RESTART left some uncertainties. First, although there 
was no evidence of heterogeneity of the effects of anti-
platelet therapy by ICH location in RESTART, participants 
with non-lobar ICH might have benefited more than 
people with lobar ICH.19,20 Second, RESTART recruited 
one in 12 eligible patients and the average ICH volume 
was approximately 4 mL,21 so the generalisability of the 
trial’s event rates needs to be established in comparison 
with population-based data from unselected patients with 
ICH.22 Third, there was no heterogeneity of the effects of 
antiplatelet therapy for ICH survivors with comorbid AF, 
but if these patients have especially high risks of systemic 
embolism then oral anticoagulation might be warranted.23
Therefore, we analysed two contemporary, prospective, 
population-based cohort studies in the UK to address 
three uncertainties: first, the absolute and relative risks 
of recurrent ICH and ischaemic stroke, stratified by ICH 
location and comorbid AF, in unselected patients with 
ICH; second, the risks of all serious vascular events after 
ICH; and third, the generalisability of RESTART.
Methods 
Cohort studies 
The Oxford Vascular Study (OXVASC) is an ongoing 
population-based inception cohort study of all acute 
vascular events in a population of 92 728 individuals, 
registered with 100 general practitioners in nine general 
practices in Oxfordshire, UK.24 OXVASC used multiple 
overlapping methods to achieve near-complete ascertain-
ment of all cases:24 (1) a daily, rapid-access clinic to which 
participating general practitioners and the local emergency 
department team referred individuals with suspected TIA 
or minor stroke; (2) daily searches of admissions to medi-
cal, stroke, neurology, and other relevant wards; (3) daily 
searches of the local emergency department attendance 
Research in context
Evidence before this study
We searched Ovid MEDLINE (from 1946), Embase (from 1976), 
and bibliographies of relevant publications on June 18, 2020 
(appendix p 2), for cohort studies, published in English in full, 
of any serious vascular event after intracerebral haemorrhage 
(ICH) from database inception to June 18, 2020. We found 
21 published studies. Mostly hospital-based cohort studies, 
with unavoidable selection biases, have described the risks 
and risk factors for selected outcomes after ICH over short 
durations of follow-up. The absolute event rate ranged 
between 1·1 and 11·6 per 100 patient-years for recurrent ICH 
and between 1·0 and 3·0 per 100 patient-years for ischaemic 
stroke. No study reported the risks of serious vascular events 
after ICH. Six studies reported the risks of recurrent ICH versus 
ischaemic stroke by ICH location, with conflicting results. 
No study compared risks by comorbid atrial fibrillation (AF). 
Recently, RESTART found that after ICH associated with 
antithrombotic drug use, survivors had a non-significantly 
lower risk of recurrent ICH after starting antiplatelet therapy 
compared with not receiving these drugs. However, the 
generalisability of RESTART to real-world practice is unknown.
Added value of this study
These pooled analyses provide data from two contemporary 
population-based cohort studies, free of selection bias, with 
prospective follow-up for not only recurrent stroke, but also 
for all serious vascular events after ICH. The rates of ischaemic 
stroke and recurrent ICH in our cohort studies support the 
generalisability of the event rates observed in RESTART. 
A meta-analysis of our cohort studies and another four 
similar published cohorts established lobar ICH as a risk factor 
for recurrent ICH, but not for ischaemic stroke after ICH. 
We have identified comorbid AF as the major risk factor for 
ischaemic stroke and all serious vascular events after ICH.
Implications of all the available evidence
In clinical practice, ICH survivors can be stratified into groups 
at higher risk of recurrent ICH, ischaemic stroke, or all serious 
vascular events according to ICH location and comorbid AF. 
The high risk of ischaemic stroke and all serious vascular 
events for ICH survivors with AF mandates rapid completion 
of ongoing randomised controlled trials of antithrombotic 
drugs or left atrial appendage occlusion to reduce these risks.
See Online for appendix
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register; (4) daily searches of in-hospital death records via 
the bereavement office; (5) monthly searches of all death 
certificates and coroner’s reports for out-of-hospital deaths; 
(6) monthly searches of general prac titioner diagnostic 
coding and hospital discharge codes; and (7) monthly 
searches of brain and vascular imaging referrals. We 
included patients diagnosed with ICH by brain imaging 
or pathological examination between April 1, 2002, and 
Sept 28, 2018, inclusive.
The Lothian Audit of the Treatment of Cerebral 
Haemorrhage (LATCH) is an ongoing population-based 
audit and inception cohort study of adults aged at least 
16 years with ICH in the National Health Service (NHS) 
Lothian health board region of Scotland, UK (mid-2012 
population 843 733).5 LATCH also used multiple over-
lapping methods to achieve near-complete ascertainment 
of data: (1) notifications from a collaborative Lothian-
wide network of physicians, neurologists, neurosurgeons, 
radiolo gists, pathologists, stroke specialist nurses, and 
stroke audit personnel; (2) daily review of all brain imaging; 
(3) quarterly searches of the electronic patient records 
system in secondary care; (4) annual searches of death 
certificates and coroner’s reports for sudden deaths; and 
(5) annual searches of NHS Lothian records in the Scottish 
Stroke Care Audit. We included patients diagnosed with 
ICH by brain imaging or pathological examination 
between June 1, 2010, and May 31, 2013, inclusive.
Written informed consent or assent from relatives was 
obtained from all participants in OXVASC, which was 
approved by the local research ethics committee (OREC A: 
05/Q1604/70). LATCH was approved by the NHS Lothian 
Caldicott Guardian on the basis that patients in NHS 
Lothian were informed about the use of their data for 
audit by information leaflets, which informed patients 
and their carers about their right to opt out; these analyses 
of an anonymised extract of data did not require research 
ethics committee approval. We planned the pooling, 
outcomes, and analyses of the cohorts prospectively, after 
they were presented simultaneously at the European 
Stroke Organisation conference in 2019.
In both studies, demographic data, vascular risk factors, 
and medication used before ICH were collected from 
medical records or face-to-face interviews and cross-
referenced with primary care records. Brain CT imaging 
was the first-line imaging method used for patients with 
stroke in both studies (unless presentation was delayed, 
in which case brain MRI was used). A dedicated study 
neuroradiologist reviewed brain imaging centrally to 
confirm ICH and categorised ICH location as lobar or 
non-lobar (involving the basal ganglia, thalamus, inter-
nal or external capsule, brainstem, or cerebellum). In 
LATCH, the Cerebral Haemorrhage Anatomical Rating 
Instru ment (CHARTS) was used and in OXVASC the 
principles used were broadly similar to the subsequently 
published CHARTS.25 Selected cases were further inves-
tigated for underlying causes using CT or magnetic 
resonance (MR) angiography, CT or MR venography, or 
catheter angiography or brain MRI, especially in people 
younger than 50 years, in the presence of signs suggestive 
of an underlying structural cause,26 or in the absence of 
other risk factors.27 For the current analysis, we included 
consecutive patients with first ever ICH without evidence 
of it being secondary to trauma, thrombolysis, haemor-
rhagic transformation of infarction, or underlying macro-
vascular or neoplastic causes. We excluded adults with 
exclusively extra-axial intracranial haemorrhage.
Patients’ physicians usually stopped premorbid anti-
thrombotic treatment immediately after ICH diagnosis, 
and the decision to restart an antithrombotic drug was 
based on physicians’ clinical judgment of the risk and 
benefit for each patient.
In OXVASC,24 patients were followed up face-to-face 
at 1, 6, 12, 60, and 120 months by a study nurse or physician 
supplemented by review of primary care records. OXVASC 
personnel followed up patients who had moved out of the 
study area by telephone at the same timepoints as face-to-
face follow-up. In LATCH,5 patients were followed up 
annually using postal or telephone questionnaires sent to 
each adult’s general practitioner to ascertain vital status 
and the occurrence of any out come events. LATCH 
personnel recorded outcomes and causes of deaths during 
follow-up according to clinical information obtained by 
direct follow-up, via primary care records, or by record 
linkage to hospital admissions and death records.
Outcomes 
The primary outcomes in this study were recurrent ICH, 
ischaemic stroke, or any serious vascular event (non-
fatal stroke, non-fatal myocardial infarction, or vascular 
death).28,29 We defined vascular death as death within 
30 days following and due to recurrent symptomatic ICH, 
extra cranial haem orrhage, ischaemic stroke, myocardial 
infarc tion, peripheral artery occlusion, mesenteric ischae-
mia, cen tral retinal arterial occlusion, symptomatic deep 
vein throm bosis, symptomatic pulmonary embolism, 
sudden cardiac death (with symptoms suggestive of myo-
car dial infarction or evidence of arrhythmia), symptom-
atic stroke of uncertain subtype, or revascularisation 
procedures.19
Systematic review and meta-analysis 
LL searched Ovid MEDLINE (from 1946) and Embase 
(from 1974) using the terms detailed in the appendix (p 2) 
for any ICH cohort study reporting absolute event rates (or 
total person-years of follow-up and numbers of out-
comes) of ischaemic stroke or recurrent ICH stratified 
by ICH location (lobar vs non-lobar) that were pub-
lished in English in full (ie, not just as a conference 
abstract) up to June 18, 2020. We excluded studies that 
were restricted to a selected ICH subgroup (eg, ICH attri-
buted to hypertension alone, cerebral amyloid angiopathy, 
or antithrombotic treatment), that included 50 patients or 
fewer, or had an average follow-up of 1 year or less. 
LL and MTCP identified eligible studies inde pendently, 
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consulted a third reviewer (PMR) in case of disagreement, 
and screened bibliographies of included studies for 
additional studies. We extracted information on the 
population studied, study period (duration), sample size, 
person-years of follow-up, and total numbers of recurrent 
ICH and ischaemic strokes stratified by index ICH 
location. We calculated the risk ratio of ischaemic stroke or 
recurrent ICH after lobar versus non-lobar ICH in 
OXVASC and LATCH and in included cohort studies, and 
then pooled the risk ratios using a random effects model 
with inverse variance weighting; we used the I² statistic to 
measure heterogeneity between studies.
Statistical analysis 
We harmonised the classification and coding of cate-
gorical covariates in the two cohorts, analysed each 
cohort separately, and then did the same analyses using 
a pooled dataset of all individual patient-level data 
from both cohorts. We did complete analyses without 
imputation and report missing data where applicable. 
We compared baseline characteristics of patients with 
versus without the candidate risk factors (lobar vs 
non-lobar ICH and presence vs absence of comorbid AF 
[defined as any known history of AF or new AF at the 
time of ICH presentation]) with the χ² test for categorical 
variables and t test for continuous variables.
We calculated absolute event rates for the primary 
outcomes separately for each cohort. We then calculated 
pooled estimates using an inverse variance weighted 
random effect meta-analysis to account for potential 
heterogeneity between the two cohorts. We derived 
figures for the cumulative incidence of outcomes from 
Kaplan-Meier analyses until the occurrence of the first 
outcome during follow-up or censoring at death, last 
available follow-up, or Sept 28, 2018, in OXVASC or 
Feb 14, 2018, in LATCH. Owing to the differences in 
follow-up duration between the two studies, we also did 
sensitivity analyses using follow-up data censored at 
5 years when pooling both studies.
We applied Poisson regression models using the 
number of events as the outcome, including the person-
years at risk as an offset to estimate the absolute event 
rates with 95% CIs (using all follow-up and also censoring 
at 5 years in sensitivity analyses). We used unadjusted Cox 
regression models to compare the risk of the first 
occurrence of each outcome (ischaemic stroke, recurrent 
ICH, or any serious vascular event) during follow-up 
to 5 years according to the candidate risk factors (ICH 
location and comorbid AF). We also did Cox regression 
adjusting for study clustering using different approaches 
including a stratified Cox regres sion, a two-stage random 
effects meta-analysis, and a Cox regression model with the 
cohort as a covariate. In view of the potential competing 
risk of death, we also did sensitivity analyses using 
competing risk models (Fine-Gray sub-distribution hazard 
model).30 We did additional sensitivity analyses stratified 
by use of antithrombotic therapy before ICH.
In the subgroup of patients who had used anti-
thrombotic therapy until ICH, we compared the risks 
of ischaemic stroke and recurrent ICH in the two 
population-based cohort studies with the same risks for 
the participants allocated to avoid antithrombotic therapy 
in RESTART.
All analyses were done in SPSS version 22 or Stata 15.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results 
674 patients (mean age 74·7 years [SD 12·6], 320 [47%] 
men; table 1) presented with incident first-ever ICH 
(419 in LATCH and 255 in OXVASC), of whom 317 (47%) 
had lobar ICH, 355 (53%) had non-lobar ICH, and 
two (<1%) had fatal ICH that occurred out of the study area 
without accessible details of the ICH location. These 









Age, years 74·7 (12·6) 75·5 (11·6) 74·1 (13·5) 0·16
Sex
Male 320 (47%) 139 (44%) 181 (51%) 0·064
Female 354 (53%) 178 (56%) 174 (49%) ··
Medical history
Previous occlusive vascular disease† 217/673 (32%) 103/317 (32%) 112/354 (32%) 0·81
Hypertension 429/673 (64%) 178/317 (56%) 250/354 (71%) <0·0001
Diabetes 83/674 (12%) 37/317 (12%) 46/355 (13%) 0·61
Hyperlipidaemia 134/673 (20%) 58/317 (18%) 76/354 (21%) 0·31
Atrial fibrillation 147/673 (22%) 63/317 (20%) 84/354 (24%) 0·23
Current smoker 116/665 (17%) 54/311 (17%) 62/352 (18%) 0·93
Medication before ICH
Antithrombotic drugs‡ 344/674 (51%) 172/317 (54%) 171/355 (48%) 0·12
Anticoagulant drugs 110/674 (16%) 52/317 (16%) 58/355 (16%) 0·98
Antiplatelet drugs 250/674 (37%) 128/317 (40%) 121/355 (34%) 0·092
Antihypertensive drugs 329/674 (49%) 142/317 (45%) 186/355 (52%) 0·049
Statins 222/644 (34%) 117/304 (38%) 104/338 (31%) 0·040
Medication at hospital or clinic discharge§
Antithrombotics¶ 22/378 (6%) 12/182 (7%) 10/196 (5%) 0·54
Anticoagulant drugs 7/378 (2%) 5/182 (3%) 2/196 (1%) 0·21
Antiplatelet drugs 16/378 (4%) 8/182 (4%) 8/196 (4%) 0·88
Antihypertensive drugs 229/378 (61%) 89/182 (49%) 140/196 (71%) <0·0001
Data are mean (SD), number (%), or n/N (%). Missing data in Lothian Audit of the Treatment of Cerebral Haemorrhage: 
previous occlusive vascular disease (n=1), hypertension (n=1), hyperlipidaemia (n=1), atrial fibrillation (n=1), smoking 
(n=2), and statins (n=30). Missing data in Oxford Vascular Study: smoking (n=8). ICH=intracerebral haemorrhage. 
*Two patients with unknown location owing to out-of-area death and brain imaging not accessible. †Any history of 
transient ischaemic attack, stroke, myocardial infarction, or peripheral vascular disease. ‡16 patients were on both 
anticoagulant and antiplatelet drugs. §Excluding patients who died before discharge. ¶One patient was on both 
anticoagulant and antiplatelet drugs. 
Table 1: Characteristics of all patients with first-ever ICH at diagnosis and hospital discharge, stratified 
by ICH location
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by ICH location. The cohorts were similar at baseline, 
apart from significantly higher frequencies of smoking 
and use of antiplatelet drugs and statins before ICH in 
LATCH, and a higher frequency of antihypertensive 
drug use at hospital or clinic discharge in OXVASC 
(appendix p 3).
Patients with lobar ICH were less likely than patients 
with non-lobar ICH to have been diagnosed with 
hypertension (178 [56%] of 317 vs 250 [71%] of 354; 
p<0·0001) and to have taken blood pressure lowering 
drugs both before ICH (142 [45%] of 317 vs 186 [52%] 
of 355; p=0·049) and at discharge from hospital (89 [49%] 
of 182 vs 140 [71%] of 196; p<0·0001), whereas patients 
with lobar ICH were more likely than patients with non-
lobar ICH to have taken a statin before ICH (117 [38%] 
of 304 vs 104 [31%] of 338; p=0·040), but there were no 
other baseline differences by ICH location (table 1). 
Baseline characteristics by ICH location were broadly 
similar in analyses of each cohort (appendix pp 4, 5).
147 (22%) of 673 patients had comorbid AF at presenta-
tion with ICH; they were older, more likely to have 
peripheral vascular disease and hypertension, and more 
likely to have used oral anticoagulation and blood pres-
sure lowering drugs before ICH than those without AF 
(appendix p 6).
Before ICH, 344 (51%) of 674 patients were taking 
antithrombotic therapy, which was continued by only 
22 (6%) of 378 survivors at discharge from hospital or 
clinic, with no significant differences by ICH location 
(table 1) or study cohort (appendix pp 3–5). Although 
patients with AF were more likely to be on antithrombotic 
drug therapy at hospital discharge, only five (6%) of 84 ICH 
survivors with comorbid AF took oral anticoagulation at 
hospital or clinic discharge (appendix p 6).
During 1553 patient-years of follow-up, 492 deaths, 
46 recurrent ICHs, 25 ischaemic strokes, and 118 serious 
vascular events were reported. The details of the recur-
rent ICH and ischaemic strokes are presented in the 
appendix (p 7). Overall, the absolute event rate of recurrent 
ICH (3·2 per 100 patient-years, 95% CI 2·0–5·1) was 
greater than the rate of ischaemic stroke (1·7 per 
100 patient-years, 0·8–3·3; p=0·010); the absolute event 
rate of any serious vascular event was 7·9 per 100 patient-
years (95% CI 4·3–14·4; table 2). These risks were similar 




















OXVASC (n=255)† 15/626 2·4 (1·3–4·0) 7/637 1·1 (0·4–2·3) 35/616 5·7 (4·0–7·9)
LATCH (n=419) 31/788 3·9 (2·7–5·6) 18/801 2·3 (1·3–3·6) 83/785 10·6 (8·4–13·1)
Pooled 46/1414 3·2 (2·0–5·1) 25/1438 1·7 (0·8–3·3) 118/1401 7·9 (4·3–14·4)
ICH location
OXVASC
Lobar (n=109) 11/275 4·0 (2·7–7·2) 4/275 1·5 (0·4–3·7) 23/271 8·5 (5·4–12·7)
Non-lobar (n=144) 4/351 1·1 (0·3–2·9) 3/362 0·8 (0·2–2·4) 12/345 3·5 (1·8–6·1)
LATCH
Lobar (n=208) 22/384 5·7 (3·6–8·7) 8/388 2·1 (0·9–4·1) 42/384 10·9 (7·9–14·8)
Non-lobar (n=211) 9/404 2·2 (1·0–4·2) 10/412 2·4 (1·2–4·5) 41/401 10·2 (7·3–13·9)
Pooled
Lobar (n=317) 33/659 5·1 (3·6–7·2) 12/664 1·8 (1·0–3·2) 65/656 10·0 (7·8–12·8)
Non-lobar (n=355) 13/755 1·8 (1·0–3·3) 13/774 1·6 (0·6–4·4) 53/745 6·1 (2·1–17·6)
Comorbid AF
OXVASC
AF (n=57) 1/81 1·2 (0·0–6·9) 6/81 7·4 (2·7–16·1) 9/79 11·5 (5·2–21·8)
No AF (n=198) 14/545 2·6 (1·4–4·3) 1/556 0·2 (0·0–1·0) 26/537 4·8 (3·2–7·1)
LATCH
AF (n=90) 6/126 4·8 (1·8–10·4) 7/127 5·5 (2·2–11·4) 23/126 18·2 (11·6–27·4)
No AF (n=328) 25/662 3·8 (2·4–5·6) 11/674 1·6 (0·8–2·9) 60/659 9·1 (7·0–11·7)
Pooled
AF (n=147) 7/207 3·3 (1·0–10·7) 13/208 6·3 (3·7–10·9) 32/205 15·5 (10·0–24·1)
No AF (n=526) 39/1207 3·2 (2·2–4·7) 12/1230 0·7 (0·1–5·6) 86/1196 6·8 (3·6–12·5)
AF=atrial fibrillation. ICH=intracerebral haemorrhage. LATCH=Lothian Audit of the Treatment of Cerebral Haemorrhage. OXVASC=Oxford Vascular Study. *Non-fatal stroke or 
myocardial infarction, or vascular death. †Cause of death data missing for three patients because patients moved out of the area or abroad.
Table 2: Absolute event rates of first recurrent ICH, ischaemic stroke, or any serious vascular event in patients with ICH stratified by ICH location and 
history of AF
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in sensitivity analyses censoring follow-up at 5 years 
(appendix p 8).
The absolute event rate of recurrent ICH was higher 
after lobar (5·1 per 100 patient-years, 95% CI 3·6–7·2) 
versus non-lobar ICH (1·8 per 100 patient-years, 1·0–3·3; 
HR 3·2, 95% CI 1·6–6·3; p=0·0010; table 2). However, 
there was no evidence that the risk of ischaemic stroke 
differed by ICH location (lobar 1·8 per 100 patient-years, 
95% CI 1·0–3·2 vs non-lobar 1·6 per 100 patient-years, 
0·6–4·4; HR 1·1, 95% CI 0·5–2·8; p=0·76). The absolute 
event rate of recurrent ICH (5·1 per 100 patient-years, 
95% CI 3·6–7·2) exceeded the risk of ischaemic stroke 
after lobar ICH (1·8 per 100 patient-years, 1·0–3·2). 
Finally, the absolute event rate of any serious vascular 
event was numerically greater after lobar (10·0 per 
100 patient-years, 95% CI 7·8–12·8) than non-lobar ICH 
(6·1 per 100 patient-years, 2·1–17·6; HR 1·4, 95% CI 
1·0–2·1; p=0·08). These findings were similar in separate 
analyses of each cohort (table 2); in sensitivity analyses 
censoring follow-up at 5 years (appendix p 8); after 
adjusting for clustering (appendix p 9); after using 
competing risk models (appendix pp 10, 11); in a meta-
analysis of LATCH, OXVASC, and another five cohort 
studies that reported these risks stratified by ICH location 
(appendix pp 12, 13; figure 1);8,9,13,31,32 and in pooled ana-
lyses stratified by antithrombotic drug use before ICH 
(appendix p 14). Furthermore, pooled analyses of the time 
course of events in LATCH and OXVASC showed that the 
higher risk of recurrent ICH after lobar ICH (HR 3·2, 
95% CI 1·6–6·3; p=0·0010) was most marked in the 
90 days after ICH (6·0, 1·3–27·2; p=0·019; figure 2).
Comorbid AF conferred a higher risk of ischaemic 
stroke (AF 6·3 per 100 patient-years, 95% CI 3·7–10·9, vs 
no AF 0·7 per 100 patient-years, 0·1–5·6; HR 8·2, 95% CI 
3·3–20·3; p<0·0001) and any serious vascular event 
(15·5 per 100 patient-years, 10·0–24·1, vs 6·8 per 
100 patient-years, 3·6–12·5; HR 1·78, 95% CI 1·16–2·74; 
p=0·0090), but comorbid AF did not modify the risk of 
recurrent ICH (3·3 per 100 patient-years, 1·0–10·7, vs 
3·2 per 100 patient-years, 2·2–4·7; HR 0·9, 95% CI 
0·4–2·1; table 2; figure 2). 13 (52%) of the 25 ischaemic 
strokes were AF related, but only seven (15%) of the 
46 patients with recurrent ICH had AF. The associations 
with comorbid AF were similar in separate analyses of 
each cohort (table 2), in sensitivity analyses censoring 
follow-up at 5 years (appendix p 8), after adjusting for 
clustering (appendix p 9), and after using a competing 
risk model (appendix p 15). Stratification of the cohort 
according to presence versus absence of both comorbid 
AF or occlusive vascular disease before ICH confirmed no 
association between comorbid AF and recurrent ICH in 
all four groups, but the absolute event rate of any serious 
vascular event after ICH and comorbid AF alone (11·3 per 
100 patient-years, 95% CI 6·3–20·4) was numerically 
higher when accompanied by a history of occlusive vascu-
lar disease (19·4 per 100 patient-years, 95% CI 9·0–41·7; 
appendix p 16). Findings were similar in an analysis 
censoring at 5-year follow-up (appendix p 17).
Considering both lobar ICH location and comorbid AF, 
there was no evidence that the absolute event rates of 
recurrent ICH and ischaemic stroke differed, apart from 
patients with lobar ICH and no history of AF for whom the 
risk of recurrent ICH was greater than the risk of ischaemic 
stroke (5·2 per 100 patient-years, 95% CI 3·6–7·5, vs 
0·9, 0·2–4·8; p=0·00034; appendix p 18). Findings were 
similar in an analysis censoring at 5-year follow-up 
(appendix p 19). Nonetheless, in keeping with the high risk 
for all serious vascular events in patients with comorbid 
AF (table 2), the risk of any serious vascular event was 
numerically higher for patients with lobar ICH and 
Figure 1: Pooled analyses of the relative risks of recurrent ICH and ischaemic stroke following lobar ICH versus 
non-lobar ICH
ICH=intracerebral haemorrhage. LATCH=Lothian Audit of the Treatment of Cerebral Haemorrhage. 
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comorbid AF (14·6 per 100 patient-years, 95% CI 8·6–24·6) 
than for patients with lobar ICH in sinus rhythm (9·1 per 
100 patient-years, 6·6–12·6; HR 1·3, 95% CI 0·7–2·5; 
p=0·42; appendix p 18). Findings were similar in an 
analysis censoring at 5-year follow-up (appendix p 19).
In the pooled cohorts, 344 (51%) of 674 patients were 
taking antithrombotic therapy before ICH (table 1). There 
was no evidence that the risk of recurrent ICH differed by 
use of antithrombotic therapy before ICH (yes vs no; 
HR 1·2, 95% CI 0·6–2·1), but the risk of ischaemic stroke 
was higher in patients who were taking antithrombotic 
therapy before ICH than those who were not (3·0, 
1·2–7·5; p=0·020). Results were also consistent in 
analyses adjusting for clustering (appendix p 9). These 
patients might benefit from antithrombotic therapy after 
ICH, but 356 (94%) of 378 ICH survivors were not 
on antithrombotic drugs at hospital or clinic discharge. 
Therefore, we compared patients in the pooled cohorts 
who had taken antithrombotic therapy before ICH and 
met the eligibility criteria for the RESTART trial19 with 
patients who were allocated to not receive antiplatelet 
therapy in the RESTART trial to establish the external 
validity of RESTART (table 3; appendix p 20). Patients with 
ICH in the cohort studies were older and were more likely 
Figure 2: 5-year risks of first recurrent ICH, ischaemic stroke, or serious vascular event stratified by ICH location and by AF in pooled analyses of OXVASC and LATCH
Serious vascular events were non-fatal stroke or myocardial infarction, or vascular death. AF=atrial fibrillation. ICH=intracerebral haemorrhage. LATCH=Lothian Audit of the Treatment of Cerebral 
Haemorrhage. OXVASC=Oxford Vascular Study.
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Log-rank p=0·00052 Log-rank p=0·85
AF
No AF
Log-rank p=0·76 Log-rank p<0·0001
Log-rank p=0·081 Log-rank p=0·0081
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to have non-lobar ICH and comorbid AF in comparison 
with the RESTART participants, but the absolute event 
rate of recurrent ICH and ischaemic stroke did not differ 
(table 3). These findings were consistent in sensitivity 
analyses restricted to each cohort and when restricting 
analyses to 5 years of follow-up (appendix pp 21, 22). 
When using ICH location to stratify comparisons between 
the pooled cohorts and allocation to not receive antiplatelet 
therapy in RESTART, we did not find differences in the 
absolute event rate of ischaemic stroke and recurrent 
ICH, apart from a higher risk of recurrent ICH after non-
lobar ICH in RESTART (5·5 per 100 patient-years, 95% CI 
2·5–8·5) compared with the cohort studies (1·1 per 
100 patient-years, 0·1–3·9; p=0·018; appendix p 23). 
Findings were similar when using the 5-year follow-up 
data (appendix p 24).
Discussion 
In pooled analyses of 674 patients with first-ever ICH in 
two recent, prospective, population-based cohort studies, 
we found similar overall absolute event rates of recurrent 
ICH and ischaemic stroke and a high absolute event rate 
of any serious vascular event. Lobar ICH location was the 
principal risk factor for recurrent ICH. Comorbid AF 
was the principal risk factor for ischaemic stroke and 
all serious vascular events; the risks of these events 
were even greater in patients with a history of occlusive 
vascular disease. The risk of recurrent ICH was greater 
than the risk of ischaemic stroke only for patients with 
lobar ICH without comorbid AF. The risk of any serious 
vascular event was greater for patients with lobar ICH 
who had comorbid AF compared with patients in sinus 
rhythm. Participants allocated to not receive antiplatelet 
therapy in RESTART had similar absolute event rates of 
recurrent ICH and ischaemic stroke to those for the 
patients in the real-world pooled population-based 
studies who fulfilled eligibility criteria for RESTART.
Although hospital-based studies have not been 
consistent in identifying lobar ICH location as a risk 
factor for recurrent ICH, this was a consistent risk factor 
in our population-based studies and in a meta-analysis of 
all studies with the required data. One explanation for 
this finding is that moderate-to-severe cerebral amyloid 
angiopathy—which is a bleeding-prone vasculopathy that 
portends a particularly high risk of recurrent ICH in 
patients with imaging biomarkers of this disease4—
underlies 58% of lobar ICHs, with 72% of patients also 
having moderate-to-severe small vessel disease.3 Another 
explanation is that only 49% of lobar ICH survivors took 
antihypertensive therapy at hospital discharge compared 
with 71% of non-lobar ICH; in the PROGRESS trial, 
blood pressure lowering reduced the risk of recurrent 
ICH by 49%,33 but use of antihypertensive treatment and 
adequate reduction of blood pressure are not always 
achieved in clinical practice, as reported by others.31,34 
These explanations likely contributed to the risk of 
recurrent ICH being highest early after lobar ICH.8,16 
Despite the difference in prevalence and treatment of 
high blood pressure by ICH location, lobar ICH location 
did not influence the risk of ischaemic stroke, probably 
because risk factors for occlusive vascular disease did not 
differ by ICH location.
Comorbid AF was associated with a more than eight 
times increased risk of ischaemic stroke and a doubling 
of the risk of any serious vascular event. This finding is 
consistent with expectations from studies of patients with 
AF, but no history of ICH. The CHA2DS2-VASc score is 
used for risk stratification of patients with AF, but its 
performance seems poor when applied to patients with 
ICH,35 although we found that risk stratification by history 
of occlusive vascular disease alone might be promising.
Considering these two risk factors together, we found 
that the risk of recurrent ICH was greater than the risk of 
ischaemic stroke solely in patients with lobar ICH and no 
history of AF (38% of all patients with ICH). However, the 
risk of any serious vascular event remained higher for 
patients with comorbid AF than for those in sinus rhythm 
after both lobar and non-lobar ICH. We found that 6% of 
ICH survivors started antithrombotic drugs at hospital 
discharge, which is lower than in a previous multicentre 
study,36 and the event rate of ischaemic stroke was 6·3%, 
which is similar to estimates from the placebo arms of 
the early prevention trials in patients with AF, but without 
ICH.37,38 Therefore, we speculate that the priority for 















Mean age, years 76 76 79 0·00010
Sex
Male 360 (67%) 187 (70%) 118 (48%) <0·0001
Female 177 (33%) 82 (30%) 128 (52%) ··
Previous hypertension 401 (75%) 207 (77%) 198 (80%) 0·33
Previous diabetes 127 (24%) 70 (26%) 42 (17%) 0·013
Previous atrial fibrillation 92 (17%) 50 (19%) 130 (53%) <0·0001
Lobar ICH location 332 (62%) 166 (62%) 116 (47%)† 0·00094
Risk of outcomes
Recurrent ICH
Number 35 23 13 ··
Rate (95% CI), per  
100 patient-years
3·3 (2·2–4·4)† 4·4 (2·6–6·1) 3·5 (1·9–6·0) 0·52
Ischaemic stroke
Number 46 27 13 ··
Rate (95% CI), per  
100 patient-years
4·4 (3·2–5·7) 5·3 (3·3–7·2) 3·4 (1·9–5·9) 0·19
ICH=intracerebral haemorrhage. OXVASC=Oxford Vascular Study. LATCH=Lothian Audit of the Treatment of Cerebral 
Haemorrhage. *Patients in OXVASC and LATCH taking antithrombotic drugs before ICH for atrial fibrillation, previous 
transient ischaemic attack, ischaemic stroke, stroke of unknown subtype, peripheral artery disease, or myocardial 
infarction. †Data missing for one patient. 
Table 3: Comparison of RESTART and the pooled cohort of OXVASC and LATCH using all follow-up data
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risk of recurrent ICH (by blood pressure lowering and 
the search for specific inter ventions for cerebral amyloid 
angiopathy),39 whereas for other patients—especially 
those with comorbid AF—the priority seems to be reduc-
tion of all serious vascular events with blood pressure 
lowering and antithrombotic drugs.
These real-world population-based studies provided 
some support for the external validity of RESTART. 
Although patients in our population-based studies were 
older, more likely to be female, and had a higher pre-
valence of comorbid AF with larger volumes of ICH 
compared with participants in RESTART, the overall risks 
of recurrent ICH and ischaemic stroke were comparable 
with the risks experienced by participants allocated to not 
receive antiplatelet therapy in RESTART. The numerically 
higher risk of ischaemic stroke in RESTART is perhaps 
explained by the fact that the decision to enrol patients in 
the trial was dependent on clinical equipoise and that 
RESTART investigators might have tended to include 
patients with higher risks of ischaemic stroke for whom 
the benefits of antiplatelet drugs were judged to be 
greater. The risk of recurrent ICH after non-lobar ICH 
was higher in RESTART than in our pooled cohorts, 
perhaps reflecting the inclusion of only high-risk patients 
with non-lobar ICH in RESTART (ie, clinicians might feel 
more confident treating patients with non-lobar ICH at 
lower risk of recurrence in everyday clinical practice); 
these differences do not appear to be attributable to the 
effects of antiplatelet therapy in RESTART, which might 
have reduced the risk of recurrent ICH after non-lobar 
ICH (adjusted HR 0·31, 95% CI 0·10–0·96).19
The strengths of our study include the pooling of 
individual patient-level data from two contemporaneous 
population-based studies, with a consistent inception 
point at the time of first-ever ICH, and prospective 
long-term follow-up. Our findings were consistent in 
various stratified analyses and sensitivity analyses using 
different methods and timeframes. But our study also has 
limitations. First, brain CT was the imaging method used 
in all patients, so we focused on ICH location, which 
was rated for all patients; we did not investigate risks 
according to MRI biomarkers of cerebral small vessel 
disease, which were available in a minority (<5%) in these 
real-world settings. Risks of recurrent ICH can be 
stratified according to imaging biomarkers of cerebral 
small vessel disease, by MRI4 or possibly CT,3 which would 
require much larger pooled analyses of cohort studies to 
further stratify absolute and relative risks of recurrent 
ICH and ischaemic stroke. Second, despite pooling 
two population-based studies, we did not have the power 
to explore interactions between ICH location, comorbid 
AF, and previous occlusive vascular disease. Third, 
although both cohorts were similar in the direc tions and 
magnitudes of the associations with risk factors of interest, 
the absolute risks of outcome events were higher in 
LATCH than OXVASC, probably owing to differences that 
we found in the prevalence of risk factors for vascular 
disease and in the uptake of secondary prevention drugs 
before ICH, as well as the known higher burden of 
cardiovascular disease in Scotland compared with 
England.40 However, the random effects model allowed us 
to take into account differences between cohorts. We did 
not adjust our estimates for the use of antithrombotic 
drugs after hospital or clinic discharge because so few 
patients started these drugs, and observa tional studies are 
not reliable for the assessment of treatment effects. 
Fourth, owing to their distinct mech anism and prognosis, 
extra-axial haemor rhages were not included in our study, 
and more data are needed to address how best to tackle 
the balance of recurrent bleeding and ischaemic stroke in 
these patients. Fifth, we focused on three risk factors for 
the outcomes of interest, but we did not analyse other 
factors such as patient disposition, functional status, and 
frailty. Finally, our results are based on a predominantly 
white popula tion5,24 and might not be generalisable to 
other countries, especially Asian populations for which 
the pattern of recurrence might differ.14
Our findings have implications for clinical practice and 
future research. Lobar ICH location can be used to stratify 
patients according to their risk of recurrent ICH, and 
comorbid AF can be used to stratify risk of ischaemic 
stroke and all serious vascular events after ICH. Given the 
apparent benefit of blood pressure lowering in reducing 
the risk of recurrent lobar ICH,41 the high frequency of 
recurrent ICH after lobar ICH should encourage greater 
use of blood pressure lowering therapy. Further research 
is needed to achieve larger sample sizes to explore risk 
stratification with greater precision and develop prog-
nostic models using the three risk factors combined (ICH 
location, comorbid AF, and history of occlusive vascular 
disease) and other risk factors of interest (eg, biomarkers 
of cerebral small vessel disease). The high risk of all 
serious vascular events after ICH, whether ischaemic or 
haemorrhagic, and the poor uptake of blood pressure 
lowering the rapy mandate more intensive approaches to 
second ary prevention; these include randomised trials of 
monitoring or therapeutic strategies to reduce blood 
pressure (NCT02699645 and NCT03863665), and a large 
randomised trial to investigate the reproducibility of the 
potentially beneficial effects of antiplatelet therapy on 
recurrent ICH and all serious vascular events seen in 
RESTART (NCT04522102). We found that for patients 
who stopped antithrombotic drugs after ICH or for those 
with known AF, the risk of ischaemic stroke was similar 
to the risk of recurrent ICH in those with lobar ICH, 
supporting the inclusion of these patients in recent and 
ongoing trials of starting versus stopping pre vious anti-
throm botic treat ment in these sub groups (NCT03996772, 
NCT03950076, NCT02565693, NCT03186729, 
NCT03243175, NCT03153150).19 The high risk of all 
serious vascu lar events, which exceed the risk of recurrent 
ICH, for ICH survivors with comorbid AF support their 
inclusion in ongoing randomised trials of oral antico-
agulants (NCT03996772, NCT03950076, NCT02565693, 
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NCT03186729, NCT03243175, NCT03153150) and scrutiny 
of the subgroup with lobar ICH by data monitoring 
committees. 
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